Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial

The Lancet Infectious Diseases

Volumn 19, Issue 9, 2019, Pages 1013-1022

  Modjarrad, Kayvon ^a   Roberts, Christine C ^c   Mills, Kristin T ^b   Castellano, Amy R ^d   Paolino, Kristopher ^a   Muthumani, Kar ^e   Reuschel, Emma L ^e   Robb, Merlin L ^d   Racine, Trina ^f   Oh, Myoung don ^g   Lamarre, Claude ^f   Zaidi, Faraz I ^e   Boyer, Jean ^h   Kudchodkar, Sagar B ^c   Jeong, Moonsup ^c   Darden, Janice M ^d   Park, Young K ^c   Scott, Paul T ^a   Remigio, Celine ^c   Parikh, Ajay P ^d   Wise, Megan C ^h   Patel, Ami ^e   Duperret, Elizabeth K ^e   Kim, Kevin Y ^e   Choi, Hyeree ^e   White, Scott ^h   Bagarazzi, Mark ^h   May, Jeanine M ⁱ   Kane, Deborah ^c   Lee, Hyojin ^c   Kobinger, Gary ^f   Michael, Nelson L ^a   Weiner, David B ^e   Thomas, Stephen J ^a   Maslow, Joel N ^c   more..

^a Walter Reed Army Institute for Research   (United States)

^b ICON Clinical Research LLC   (United States)

^c GeneOne Life Science Inc   (South Korea)

^d HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^e WISTAR INSTITUTE   (United States)

^f UNIVERSITÉ LAVAL   (Canada)

^g Seoul National University College of Medicine   (South Korea)

^h Inovio Pharmaceuticals   (United States)

ⁱ EMMES CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; DNA VACCINE; GLS 5300; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS VACCINE; VIRUS ANTIBODY; VIRUS DNA;

ABNORMAL LABORATORY RESULT; ADULT; ANTIBODY RESPONSE; ARTHRALGIA; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DNA IMMUNIZATION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; ELECTROPORATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; INJECTION SITE CONTUSION; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE SWELLING; MALAISE; MALE; MIDDLE EAST RESPIRATORY SYNDROME; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MYALGIA; NAUSEA; NORMAL HUMAN; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SEROCONVERSION; SIDE EFFECT; UNITED STATES; VACCINE IMMUNOGENICITY; BLOOD; CLINICAL TRIAL; IMMUNOLOGY; YOUNG ADULT;

ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DNA, VIRAL; FATIGUE; FEMALE; HEADACHE; HUMANS; IMMUNITY, CELLULAR; INJECTION SITE REACTION; MALE; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; VIRAL VACCINES; YOUNG ADULT;

EID: 85071376935     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(19)30266-X     Document Type: Article

References (27)

1. Corman, VM, Eckerle, I, Zaki, A, et al. Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction. Euro Surveill, 17, 2012 PII: 20285.
2. WHO. MERS situation update. http://www.emro.who.int/pandemic-epidemic-diseases/mers-cov/mers-situation-update-may-2019.html, February 2019. (Accessed 16 July 2019)
3. WHO. Middle East respiratory syndrome coronavirus (MERS-CoV). http://www.who.int/emergencies/mers-cov/en/, 2018. (Accessed 16 July 2019)
4. Bak, SL, Jun, KI, Jung, J, et al. An atypical case of Middle East Respiratory syndrome in a returning traveler to Korea from Kuwait. J Korean Med Sci, 33, 2018, e348.
5. WHO. Middle East respiratory syndrome coronavirus (MERS-CoV)—UK. http://www.who.int/csr/don/31-august-2018-mers-united-kingdom/en/, August 31, 2018. (Accessed 13 September 2018)
6. WHO. Middle East respiratory syndrome coronavirus (MERS-CoV) infection—South Korea. http://www.who.int/csr/don/12-september-2018-mers-republic-of-korea/en/, Sept 12, 2018. (Accessed 13 September 2018)
7. Oh, MD, Park, WB, Park, SW, et al. Middle East respiratory syndrome: what we learned from the 2015 outbreak in the Republic of Korea. Korean J Intern Med 33 (2018), 233–246.
8. Coleman, CM, Venkatraman, N, Liu, T, et al. MERS-CoV spike nanoparticles protect mice from MERS-CoV infection. Vaccine 35 (2017), 1586–1589.
9. Malczyk, AH, Kupke, A, Prufer, S, et al. A highly immunogenic and protective Middle East respiratory syndrome coronavirus vaccine based on a recombinant measles virus vaccine platform. J Virol 89 (2015), 11654–11667.
10. Muthumani, K, Falzarano, D, Reuschel, EL, et al. A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates. Sci Transl Med, 7, 2015, e301ra132.
11. Wang, L, Shi, W, Joyce, MG, et al. Evaluation of candidate vaccine approaches for MERS-CoV. Nat Commun, 6, 2015, 7712.
12. Choe, PG, Perera, RA, Park, WB, et al. MERS-CoV antibody responses 1 year after symptom onset, South Korea, 2015. Emerg Infect Dis 23 (2017), 1079–1084.
13. Payne, DC, Iblan, I, Rha, B, et al. Persistence of antibodies against Middle East respiratory coronavirus. Emerg Infect Dis 22 (2016), 1824–1826.
14. Zhao, J, Alshukairi, AN, Baharoon, SA, et al. Recovery from the Middle East respiratory syndrome is associated with antibody and T-cell responses. Sci Immunol, 2, 2017, eaan5393.
15. Luke, T, Wu, H, Zhao, J, et al. Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo. Sci Transl Med, 8, 2016, 326ra21.
16. Pascal, KE, Coleman, CM, Mujica, AO, et al. Pre- and postexposure efficacy of fully immunized antibodies against spike protein in a novel humanized mouse model of MERS-CoV infection. PNAS 112 (2015), 8738–8743.
17. Corman, VM, Albarrak, AM, Omrani, AS, et al. Viral shedding and antibody response in 37 patients with Middle East respiratory syndrome coronavirus infection. Clin Infect Dis 62 (2016), 477–483.
18. Park, WB, Perera, RA, Choe, PG, et al. Kinetics of serologic responses to MERS coronavirus infection in humans, South Korea. Emerg Infect Dis 21 (2015), 2186–2189.
19. Diehl, MC, Lee, JC, Daniels, SE, et al. Tolerability of intramuscular and intradermal delivery by CELLECTRA((R)) adaptive constant current electroporation device in healthy volunteers. Hum Vaccin Immunother 9 (2013), 2246–2252.
20. US Department of Health and Human Services Food and Drug Administration, Center for Biologics Evaluation and Research. Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. http://www.fda.gov/cber/guidelines.htm, September 2007. (Accessed 30 May 2015)
21. Trimble, CL, Morrow, MP, Kraynyak, KA, et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet 386 (2015), 2078–2088.
22. Maslow, JN, Vaccines for emerging infectious diseases: lessons from MERS coronavirus and Zika virus. Hum Vaccin Immunother 12 (2017), 2918–2930.
23. Bodmer, BS, Fiedler, AH, Hanauer, JRH, Prüfer, S, Mülebach, MD, Live-attenuated bivalent measles virus-derived vaccines targeting Middle East respiratory syndrome coronavirus induce robust and multifunctional T cell responses against both viruses in an appropriate mouse model. Virology 521 (2018), 99–107.
24. Munster, VJ, Wells, D, Lanmbe, T, et al. Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic DPP4 mouse model. NPJ Vaccines, 2, 2017, 28.
25. Haagmans, BL, van den Brand, JM, Raj, VS, et al. An orthopoxvirus-based vaccine reduces virus excretion after MERS coronavirus infection in dromedary camels. Science 351 (2016), 77–81.
26. Song, F, Fux, R, Provacia, LB, et al. Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies. J Virol 87 (2013), 11950–11954.
27. Volz, A, Kupke, A, Song, F, et al. Protective efficacy of recombinant modified vaccinia virus Ankara delivering Middle East Respiratory Syndrome coronavirus spike glycoprotein. J Virol 89 (2015), 8651–8656.